Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution) Overview
- Year Founded
-
2017
- Status
-
Private
- Latest Deal Type
-
Joint Venture
- Financing Rounds
-
1
Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution) General Information
Description
Developer of adeno-associated virus (AAV) gene therapies. The company's gene therapies will use Sf9 baculovirus and HEK293 mammalian cell systems and operate a process development with production facility located in the Tokyo area designed to meet international manufacturing standards, including cGMP, GCTP and PIC/S GMP requirements, enabling customers avail quality drug.
Contact Information
Corporate Office
- Japan
Corporate Office
- Japan
Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution) Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution) FAQs
-
When was Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution) founded?
Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution) was founded in 2017.
-
Where is Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution) headquartered?
Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution) is headquartered in Japan.
-
What industry is Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution) in?
Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution)’s primary industry is Drug Discovery.
-
Is Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution) a private or public company?
Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution) is a Private company.
-
What is Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution)’s current revenue?
The current revenue for Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution) is .
-
Who are Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution)’s investors?
Agilis Biotherapeutics and ONODERA GT Pharma have invested in Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process